Award
National Cancer Institute 3U54CA224019-08S1
Trajectory and Architecture of Microenvironment-Mediated Resistance in AML
Recipient
Oregon Health & Science University
Award Amount
$37,500.00
Ceiling
$37,500.00
Awarded
September 22, 2025
Identifier
3U54CA224019-08S1
Research grant awarded to Oregon Health & Science University to study drug resistance mechanisms in AML by analyzing tumor microenvironment and cellular heterogeneity, aiming to develop predictive models and combination therapies.
Description
This project aims to understand the mechanisms of acquired drug resistance in acute myeloid leukemia (AML) by studying the tumor microenvironment and cellular heterogeneity. The research focuses on mapping microenvironmental signatures, tumor cross-talk, and validating targets such as BCL2, FLT3, JAK2, MEK, and epigenetic pathways. The goal is to develop predictive models of signaling crosstalk and identify effective combination therapies to overcome resistance.